Lilly To Decide Next Steps After Formal FDA 'Nay' For First Chinese PD-1

A Chance To Reflect?

 
• By Brian Yang

The official verdict is in for sintilimab and the results are not surprising. But some view the setback for "Made In China" innovation as a chance to reflect and move forward.

FDA Complete response stamp holder
US FDA ISSUES COMPLETE RESPONSE LETTER TO LILLY/INNOVENT'S SINTILIMAB • Source: Nielsen Hobbs; the Pink Sheet | Alamy image

More from New Products

More from Scrip